Trial Profile
A Randomized, Cross-over, Open, Euglycemic Clamp Study on the Relative Bioavailability and Activity of 0.6 U/kg Insulin Glargine and 20 microg Lixisenatide, Given as On-site Mix Compared to Separate Simultaneous Injections in Subjects With Type 1 Diabetes Mellitus.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin glargine (Primary) ; Lixisenatide (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacokinetics
- 01 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Mar 2011 Actual end date (Jan 2011) added as reported by ClinicalTrials.gov.
- 29 Nov 2010 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.